Reform of the drug-review process at the Food and Drug Administration
can be achieved by streamlining the process, separating overlapping re
gulations, delegating some functions to nongovernmental bodies, and be
coming more flexible, contends Karl A. DeSante, senior research scient
ist at Lilly Laboratories.